samplefor neuroprotection
99%+ · Solution
Bulk discount
3+ pcs
€56.90
−5%
5+ pcs
€53.91
−10%
10+ pcs
€50.91
−15%
Discount is applied automatically at checkout.
Enter your email and we'll notify you when it's back:
Free shipping over €49
This product is sold strictly for in lab conditions (in vitro) research purposes. Not approved for human consumption.
Verified above 98%
98%+ verified — most batches reach 99%+
Included
Independent analysis from accredited laboratories
EU Shipping
3-7 days across the EU (Bulgaria — 1-2 days)
Secure Payment
Cash on delivery
Cerebrolysin
Neuropeptide Preparation | Neurological Recovery
In short
Mixture of neuropeptides and amino acids studied in models of neuroprotection and recovery following ischemic stress.
Best sellers
Related resources
Ready-to-use starter kit
Cerebrolysin is a complex neuropeptide preparation containing purified proteins and amino acids derived from porcine brain. At the molecular level, it delivers neurotrophic factors that interact directly with brain cells to support their survival and neural communication. Scientists are investigating it in in vitro and animal models to understand its potential in neurological injuries, post-stroke conditions, and cognitive research. While Cerebrolysin is available as an approved prescription medication in certain countries, the product offered here is strictly research-grade and is not intended for human consumption or therapeutic use.
Research reagent for laboratory use only. Not a medicine. For medical questions, consult a physician.
Scientific review
Written by
Калина Тодорова
Magister Pharmaciae, MSc Pharmacy
Reviewed by
Борис Маринов
MSc Biochemistry & Molecular Biology
Reviewed on
Cerebrolysin is a standardized neuropeptide preparation derived from purified porcine brain proteins, containing bioactive peptides and amino acids that exhibit neurotrophic and neuroprotective properties for stroke recovery, traumatic brain injury, and cognitive enhancement.
Standardized peptide extract from porcine brain 30+ years clinical track record, regulated in 50+ countries BDNF/NGF/GDNF mimicking Reduced post-stroke mRS (CARS-1)
IV/IM administration provides optimal bioavailability and brain penetration of neuropeptides and neurotrophic factors
Meta-analyses show modest cognitive improvements, though clinical significance remains debated in medical literature
Multiple RCTs demonstrate significant ADAS-cog and CIBIC+ improvements with well-documented protocols
Large meta-analysis shows significant NIHSS improvements, though other studies found no functional benefit
Dosing
The typical regimens you'll see in the published research - for reference when planning in vitro or in vivo experiments. Not medical advice.
Disclaimer
These are regimens discussed in the research literature, not medical advice. Consult a healthcare provider before use.
Timing
As soon as possible for acute conditions; morning preferred
Monitor for allergic reactions during first administration - generally well tolerated
Contraindicated in epilepsy and severe renal insufficiency per official prescribing information
Clinical evidence shows mixed results - some large studies positive, others neutral
Research integrity concerns have been raised about some published studies
Not approved in USA but used clinically in over 50 countries worldwide
Use disposable one-way infusion sets to guarantee sterility
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
TBI Systematic Review - Positive Outcomes (2023)
Humans | 10-50 mL daily | Variable duration | GCS/GOS improvements
Analysis of 8,749 TBI patients across 10 studies confirms statistically significant improvements in neurological scores
View the studyCAPTAIN II Trial - Traumatic Brain Injury (2020)
Humans | 30-50 mL daily | 10-28 days | Significant neurological improvement
Randomized controlled trial demonstrating efficacy and safety in moderate-severe TBI with improved GCS and GOS scores
View the studySubarachnoid Hemorrhage Pilot Trial (2020)
Humans | 30 mL daily | 14 days | Improved 6-month outcomes
First randomized trial in SAH patients showing promising results with 76% vs 48% favorable outcomes
View the studyNine-Trial Stroke Meta-Analysis - Positive Results (2017)
Humans | 30-50 mL daily | 10-21 days | NIHSS improvement, NNT=7.7
Largest positive meta-analysis showing significant neurological improvements in 1,879 stroke patients
View the studyConflicting Stroke Meta-Analysis - Neutral Results (2017)
Humans | Various doses | 72-hour window | No significant mRS/BI improvement
Independent meta-analysis of 1,779 patients found no significant benefits in functional outcomes, highlighting mixed evidence
View the studyAlzheimer's Disease Meta-Analysis - Mixed Evidence
Humans | 30 mL daily | 4 weeks | Modest cognitive improvements
Meta-analysis shows small but significant improvements in some cognitive measures, though clinical relevance debated
View the study
for longevity
for sexual health
No reviews yet. Be the first.
Share your experience with this peptide. We publish after a short moderation.
